logo

For the Inventor, By the Inventor

Belmont, MA, United States of America

Constantin Neagu

USPTO Granted Patents = 17 

 

 

Average Co-Inventor Count = 8.6

ph-index = 3

Forward Citations = 37(Granted Patents)


Company Filing History:

goldMedal17 out of 2,943 
 
Merck Patent Gmbh
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 12415803 - Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) (2025-09-16),
2. 11098041 - Heteroaryl compounds as BTK inhibitors and uses thereof (2021-08-24),
3. 10329270 - Heteroaryl compounds as BTK inhibitors and uses thereof (2019-06-25),
4. 10253023 - Heteroaryl compounds as BTK inhibitors and uses thereof (2019-04-09),
5. 10233160 - Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors (2019-03-19),
6. 10087166 - Cyclic amine azaheterocyclic carboxamides (2018-10-02),
7. 10080753 - Heterocyclic carboxamides as modulators of kinase activity (2018-09-25),
8. 10080750 - Aminopyrimidine derivatives for use as modulators of kinase activity (2018-09-25),
9. 9981925 - Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors (2018-05-29),
10. 9662330 - Aminopyrimidine derivatives for use as modulators of kinase activity (2017-05-30),
11. 9586938 - Cyclic amine azaheterocyclic carboxamides (2017-03-07),
12. 9440968 - Substituted pyrido[3,2-d]pyrimidines for treating cancer (2016-09-13),
13. 9321760 - Aminopyrimidine derivatives for use as modulators of kinase activity (2016-04-26),
14. 9145392 - Imidazole amines as modulators of kinase activity (2015-09-29),
15. 9139568 - Heterocyclic carboxamides as modulators of kinase activity (2015-09-22),

Title: **The Innovative Journey of Constantin Neagu**

Introduction

Constantin Neagu is a notable inventor based in Belmont, MA, who has made significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 16 patents, he has focused on developing innovative compounds with potential therapeutic applications. His work primarily emphasizes the design of novel chemicals aimed at inhibiting specific biological targets.

Latest Patents

Among his latest patents, Constantin Neagu has developed heteroaryl compounds as Bruton’s tyrosine kinase (BTK) inhibitors. One of his notable inventions includes imidazo pyridine compounds, which, along with pharmaceutically acceptable compositions, serve as effective BTK inhibitors. Another significant patent also focuses on various heteroaryl compounds, such as pyridine, pyrimidine, pyrazine, and pyridazine, emphasizing their utility as BTK inhibitors in therapeutic treatments.

Career Highlights

Constantin is currently employed by Merck Patent GmbH, where he leverages his expertise in pharmaceutical innovation. His extensive experience in synthesis and application of chemical compounds has positioned him as an influential figure within his organization. Throughout his career, he has consistently worked towards breakthroughs that not only advance scientific knowledge but also provide practical solutions for various medical challenges.

Collaborations

In his innovative pursuits, Constantin Neagu has collaborated with esteemed coworkers, including Bayard R Huck and Theresa L Johnson. These collaborations enhance the interdisciplinary nature of his work, bringing together diverse expertise to foster advancements in pharmaceutical development.

Conclusion

Constantin Neagu remains a prominent inventor whose advancements in the area of BTK inhibitors are paving the way for future therapeutic applications. His commitment to innovation at Merck Patent GmbH showcases his role in driving scientific progress and underscores the importance of collaboration in achieving groundbreaking inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…